Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and pharmacy experts are reacting to last…
Read More
A recent study has found that just more than 30 percent of people with cancer in Germany also experienced some form of clinically relevant mental health disorder. The article, published…
Read More
